Home / Knowledge Centre /

Next Generation Sequencing in Companion Diagnostic Development

The use of next generation sequencing for clinical applications is growing rapidly and the use of Next Generation Sequencing (NGS) panels is, in some areas, becoming standard of care. While panels can be highly informative from a broad perspective, it is not guaranteed that the particular SNP or insertion/ deletion of interest will be present.

When a specific targeted therapy is under evaluation and a single gene is of primary interest, there is a strong rationale for developing a NGS assay specifically for that gene.

In this webinar, Almac’s Head of Laboratory Operations Dr. Leeona Galligan presents details on the development and implementation of a clinical NGS assay for TP53 which is being used routinely for clinical trial stratification.

View Resource
Almac Logo

Diagnostic Services

Your global partner for biomarker discovery, development & commercialisation.

Genomic Services

We offer a range of genomics platform and chemistry options, alongside expert data sciences support and a full sample management service.

Clinical Trial Assays

Comprehensive development, validation & delivery service for research and clinical use assays from our global clinical laboratories in USA, Europe and APAC.

Companion Diagnostics

A collaborative Companion Diagnostic partnership approach with a deep understanding of client needs. We offer CDx development, manufacture & commercialisation services.

Learn More

Please complete this form to view the Webinar

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies